Staff editor
On the second anniversary of its launch, Ferring Pharmaceuticals’ REBYOTA remains a landmark innovation in the prevention of recurrent Clostridioides difficile.
Lonza's capsules ensures targeted intestinal delivery enhancing stability and therapeutic efficacy for LBPs and pharmaceutical applications.
Cmbio announces a strategic partnership with Nimble Science to deliver first in class high-quality, multi-omic data insights from the small intestine.
Nicola Segata, from University of Trento, investigates the intricate links between diet, microbiome composition, and cardiometabolic outcomes.
Clara Delaroque, from Institut Pasteur (France), emphasizes the critical interplay between early-life microbiota and host health, specifically how the use of common food additives impacts the susceptibility to diseases later…
The acquisition will enhance its ability to address the needs of a growing market, empowering researchers and industries worldwide.
The live biotherapeutics market is forecasted to exceed $4 billion by 2030, driven by advancements like MaaT013.
Its emergence in the respiratory health sector represents a paradigm shift, offering promising avenues for innovation and investment.
Raphaëlle Bourdet-Sicard from Danone Nutricia Research discusses a study which investigates the use of a mixed prebiotic formulation to enhance iron absorption while mitigating adverse effects on gut microbiota.
Professor Maria Rescigno explores the critical role of the gut microbiota in maintaining intestinal barrier integrity and its implications for health.
